Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque
about
Structural insights on the role of antibodies in HIV-1 vaccine and therapyA Blueprint for HIV Vaccine DiscoveryHost-pathogen interaction in HIV infectionComplex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesSomatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 NeutralizationSupersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected HumansThe Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV AntibodiesDelineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralizationGlycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodiesRecent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primatesOptimization of peptide arrays for studying antibodies to hepatitis C virus continuous epitopes.Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.Algal lectins as potential HIV microbicide candidatesN332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelopeAnalysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunizationHoning a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potencyKinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins.Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.Bovine Herpesvirus 4 Modulates Its β-1,6-N-Acetylglucosaminyltransferase Activity through Alternative SplicingDevelopment of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaquesEmergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoproteinDevelopment of prophylactic vaccines against HIV-1.HIV-host interactome revealed directly from infected cells.HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencingHIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Candidate antibody-based therapeutics against HIV-1.
P2860
Q26829461-686890BA-D1D0-43BC-A385-635E4D096E0CQ26829865-A5F078BB-716A-4A9A-8622-FB23D9B835BCQ27009024-F4B3BE7F-E0CD-43D5-BAE6-19054DE6BE4EQ27674878-59F177A6-C989-4ED9-94DB-E4AB2BCCFC1FQ27677117-006C766A-FFD7-4ADB-9EB4-6DAC3F11DF2AQ27678306-4C28F0E6-9948-4B50-8E7C-BCD1DA7C95E3Q27678312-2ECB497E-8D98-4F81-87FC-32478C41D69EQ27679123-50F9B9F3-27A0-47DA-9FF0-C3CB1CCF56B8Q27680688-EFC6DCED-EDA0-4D12-A356-A28DBEB9E96FQ27684578-3A737EE0-2E98-444A-AE89-D1699A691FFFQ28263932-B7B0A3B9-D5C0-4BF7-9AA9-671D80E53559Q30353580-EBCBD99D-CD78-4F88-9C97-FD496E30AB27Q33355730-1C748603-10F8-4C6E-AEE1-E0D7EB13C1D9Q33563569-45593281-A2D7-42EC-9FA9-DB3505E8406DQ34049077-E27C2B63-833F-4B5F-AE87-0D059331DA77Q34230556-503B6383-B2AC-47AA-BD86-D8C7CA1D59BBQ34291727-FE030872-1847-411C-8536-D610F73CA96FQ34594978-3D20D5E9-768D-449C-86DB-8A172B103756Q34611144-2C701FC3-4E7E-4B01-A077-115638F855EAQ34991017-92983EA4-8C80-4699-AC18-83399B3C8F79Q35487441-6923CCDD-5F2B-4A21-A6A0-08DB9B11BC64Q35836169-18E91AC0-D725-4158-90D8-6E26657F40D1Q35974165-FC794A0B-0100-41B0-90E3-A873593313DDQ36171962-288227B5-CB05-4568-AB66-181BA773D8FDQ36239578-73A31882-355C-48DC-8E15-B499FA7F02A1Q36248197-A699EC5B-016F-4716-B4EE-1CEF20860778Q36388754-F328ECBD-D6F9-4F7F-8B49-744B8DB8F353Q36438523-7971A8EA-2268-4859-8551-AF704EF52B88Q36524008-DA7C9B6A-76A0-4E23-8D59-EF080B8E6058Q36736392-009A9E24-824D-4485-94E2-F4DA9CBE2E97Q36760049-12B24B5A-653D-41BD-9FAD-60E7FF42A3D5Q36827168-C1FB2B0F-EC98-42D8-ACEF-7E20BB18E1B3Q37021717-FDABA537-54FC-4C33-B3D9-B231300E3229Q37036833-33822B54-B081-4313-8C86-5ED90B4F9F23Q37042563-86318772-BC3D-46C1-A68A-EA4D23196AB3Q37055800-3955581D-DEC1-44BD-AED7-DA7A2FB0125DQ37073506-D602C6C2-1F27-47A2-802A-604FE9C6D9D4Q37151457-9C486FA1-ED6B-4FEF-A40C-2B86C892ED9EQ37360774-D5964E8B-09A0-4183-9AEB-979628FB1B73Q37998496-97E61B2F-5F13-4485-8B74-D1922163C3F7
P2860
Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Rapid development of glycan-sp ...... himeric virus infected macaque
@ast
Rapid development of glycan-sp ...... himeric virus infected macaque
@en
type
label
Rapid development of glycan-sp ...... himeric virus infected macaque
@ast
Rapid development of glycan-sp ...... himeric virus infected macaque
@en
prefLabel
Rapid development of glycan-sp ...... himeric virus infected macaque
@ast
Rapid development of glycan-sp ...... himeric virus infected macaque
@en
P2093
P2860
P356
P1476
Rapid development of glycan-sp ...... himeric virus infected macaque
@en
P2093
Alejandra Ramos
Dennis R Burton
Laura M Walker
Malcolm A Martin
Masashi Shingai
Melissa D Simek
Olivia Donau
Rajeev Gautam
Reza Sadjadpour
P2860
P304
20125-20129
P356
10.1073/PNAS.1117531108
P407
P577
2011-11-28T00:00:00Z